Myocardial uptake and biochemical and hemodynamic effects of ACE inhibitors in humans

Hypertension

Volumn 41, Issue 3 I, 2003, Pages 482-487

  Zeitz, Christopher J ^a   Campbell, Duncan J ^b   Horowitz, John D ^a,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Angiotensin; Bradykinin; Enalapril; Hemodynamics; Metabolism; Myocardium

Indexed keywords

ANGIOTENSIN; BRADYKININ RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; PEPTIDE; PERINDOPRILAT;

ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY SINUS BLOOD FLOW; DRUG EFFECT; DRUG UPTAKE; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE METABOLISM; HEMODYNAMICS; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL;

ADULT; AGED; ANGINA PECTORIS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; BLOOD PRESSURE; BRADYKININ; ELECTROCARDIOGRAPHY; ENALAPRILAT; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; INDOLES; INJECTIONS, INTRAVENOUS; KINETICS; MALE; MIDDLE AGED; MYOCARDIUM;

EID: 0037336745     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000054976.67487.08     Document Type: Article

References (28)

1. GISSI-3 Gruppo. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:1115-1122.
2. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
3. Cushman DW, Wang FL, Fung WC, Harvey CM, DeForrest JM. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens. 1989;2:294-306.
4. Ruzicka M, Skarda V, Leenen FHH. Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. Circulation. 1995;92:3568-3573.
5. Horowitz JD, Powell AC. Myocardial uptake of drugs and clinical effects. Clin Pharmacokinet. 1986;11:354-371.
6. Johnston CI. Angiotensin-converting enzyme inhibitors. In: Robertson JIS, Nicholls MG, eds. The Renin Angiotensin System. London: Gower Medical Publishing; 1993;87.1-87.15.
7. Ganz W, Tamura K, Marcus HS, Donoso R, Yoshida S, Swan HJ. Measurement of coronary sinus blood flow by continuous thermodilution in man. Circulation. 1971;44:181-195.
8. Horowitz JD, Dynon MK, Woodward E, Sia ST, Macdonald PS, Morgan DJ, Goble AJ, Louis WJ. Short-term myocardial uptake of lidocaine and mexiletine in patients with ischemic heart disease. Circulation. 1986;73:987-996.
9. Jackson B, Cubela R, Johnston CI. Angiotensin-converting enzyme inhibitors: measurement of relative inhibitory potency and serum drug levels by radioinhibitor binding displacement assay. J Cardiovasc Pharmacol. 1987;9:699-704.
10. Johansen KB, Marstein S, Aas P. Automated method for the determination of angiotensin-converting enzyme in serum. Scand J Clin Lab Invest. 1987;47:411-414.
11. Lawrence AC, Evin G, Kladis A, Campbell DJ. An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal-directed antisera: measurement of eight angiotensin peptides in human plasma. J Hypertens. 1990;8:715-724.
12. Duncan A-M, Kladis A, Jennings GL, Dart AM, Esler M, Campbell DJ. Kinins in humans. Am J Physiol. 2000;278:R897-R904.
13. Raasch W, Dendorfer A, Ball B, Dominiak P. The lipophilic properties of angiotensin I-converting enzyme inhibitors do not influence their diffusion through cultured endothelium. Jpn J Pharmacol. 1999;81:346-352.
14. Nussberger J, Brunner DB, Waeber B, Biollaz J, Brunner HR. Lack of angiotensin I accumulation after converting enzyme blockade by enalapril or lisinopril in man. Clin Sci. 1987;72:387-389.
15. Delacrétaz E, Nussberger J, Püchler K, Wood AJ, Robinson PR, Waeber B, Brunner HR. Value of different clinical and biochemical correlates to assess angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol. 1994;24:479-485.
16. Danser AHJ, Koning MMG, Admiraal PJJ, Sassen LMA, Derkx FHM, Verdouw PD, Schalekamp MADH. Production of angiotensins I and II at tissue sites in intact pigs. Am J Physiol. 1992;263:H429-H437.
17. Danser AHJ, Van Kats JP, Admiraal PJJ, Derkx FHM, Lamers JMJ, Verdouw PD, Saxena PR, Schalekamp MADH. Cardiac renin and angiotensins: uptake from plasma versus in situ synthesis. Hypertension. 1994; 24:37-48.
18. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Quaife RA, Lowes BD, Roden RL, Peacock SJ, Groves BM, Raynolds MV, Bristow MR, Perryman MB. Angiotensin II formation in the intact human heart: predominance of the angiotensin-converting enzyme pathway. J Clin Invest. 1995;96:1490-1498.
19. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992;44:1-80.
20. Mancia G, Perondi R, Saino A, Tio R, Pomidossi G, Gregorini L, Zanchetti A. Haemodynamic effects of ACE inhibitors. Eur Heart J. 1990;11(suppl D):27-32.
21. Gainer JV, Morrow JD, Lovelend A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
22. Niarchos AP, Pickering TG, Case DB, Sullivan P, Laragh JH. Role of the renin-angiotensin system in blood pressure regulation: the cardiovascular effects of converting enzyme inhibition in normotensive subjects. Circ Res. 1979;45:829-837.
23. Nussberger J, Brunner DB, Waeber B, Brunner HR. True versus immunoreactive angiotensin II in human plasma. Hypertension. 1985;7(suppl I):I-1-I-7.
24. Bidiville J, Nussberger J, Waeber G, Porchet M, Waeber B, Brunner HR. Individual responses to converting enzyme inhibitors and calcium antagonists. Hypertension. 1988;11:166-173.
25. Foult J-M, Tavolaro O, Antony I, Nitenberg A. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique. Circulation. 1988;77:337-344.
26. Haber HL, Powers ER, Gimple LW, Wu CC, Subbiah K, Johnson WH, Feldman MD. Intracoronary angiotensin-converting enzyme inhibition improves diastolic function in patients with hypertensive left ventricular hypertrophy. Circulation. 1994;89:2616-2625.
27. Friedrich SP, Lorell BH, Rousseau MF, Hayashida W, Hess OM, Douglas PS, Gordon S, Keighley CS, Benedict C, Krayenbuehl HP, Grossman W, Pouleur H. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation. 1994;90:2761-2771.
28. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327:678-684.